Eighty per cent of a group of people with HIV whose current antiretroviral therapy was not working, and who had resistance to most or all currently-used drugs, achieved an undetectable viral load after being given lenacapavir, a drug currently under development that can be given just twice a year, the 11th International AIDS Society Conference on HIV Science heard this week. In the study, lenacapavir was taken as a subcutaneous (under the skin) injection in the belly.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
TheBodyPro: Can long-acting regimens solve virologic failure in heavily treatment-experienced people with HIV?
-
[Press release] TaiMed Biologics completes Phase 2b enrollment for TMB-365/380 in HIV maintenance therapy study
-
Spotlight: South Africa’s ARV programme hardly grew in 2025, according to latest estimates
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.